According to an editorial in the New England Journal of Medicine, the number of trials posted at the NIH's site with incomplete data has dropped from 26 percent before 2006 to 8 percent in the first 11 months of last year. The increase in voluntary disclosure came after some blistering criticism that large pharma companies had been essentially hiding data that raised safety issues regarding its drugs. The better response, though, is unlikely to dull the appetite in Congress for new laws requiring public disclosure, especially after the Democrats gained control of both houses of Congress.
- here's the report on trial data from The Boston Globe
Will pharma-bashing go to far? Editorial
Consumers, pharmaceutical companies differ on views of pharma industry. Release